Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 11/2012

01-11-2012 | Letter to the Editor

Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib

Authors: Eugenio Piro, Mariagrazia Kropp, Renato Cantaffa, Angelo Giuseppe Lamberti, Guido Carillio, Stefano Molica

Published in: Annals of Hematology | Issue 11/2012

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Nicolas L, Milon G, Prina E (2002) Rapid differentiation of Old World Leishmania species by LightCycler polymerase chain reaction and melting curve analysis. J Microbiol Methods 51:295–299PubMedCrossRef
2.
Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366:1561–1577PubMedCrossRef
3.
Fernández-Guerrero ML, Robles P, Rivas P, Mójer F, Muñíz G, de Górgolas M (2004) Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. Acta Trop 90:11–16PubMedCrossRef
4.
Basset D, Faraut F, Marty P, Dereure J, Rosenthal E, Mary C, Pratlong F, Lachaud L, Bastien P, Dedet JP (2005) Visceral leishmaniasis in organ transplant recipients: 11 new cases and a review of the literature. Microbes Infect 7:1370–1375PubMedCrossRef
5.
Pitini V, Cascio A, Arrigo C, Altavilla G (2012) Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia. Br J Haematol 156:1PubMedCrossRef
6.
Hirai M, Kadowaki N, Kitawaki T, Fujita H, Takaori-Kondo A, Fukui R, Miyake K, Maeda T, Kamihira S, Miyachi Y, Uchiyama T (2011) Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of toll-like receptors and endoplasmic reticulum homeostasis. Blood 117:500–509PubMedCrossRef
7.
Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Shimizu K, Sato S (2010) The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses. J Leukoc Biol 88:117–122PubMedCrossRef
8.
Basler M, Lauer C, Beck U, Groettrup M (2009) The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 183:6145–6150PubMedCrossRef
9.
Nucci M, Anaissie E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 49:1211–1225PubMedCrossRef
10.
Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC, Richardson PG (2008) Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 26:4784–4790PubMedCrossRef
Metadata
Title
Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib
Authors
Eugenio Piro
Mariagrazia Kropp
Renato Cantaffa
Angelo Giuseppe Lamberti
Guido Carillio
Stefano Molica
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 11/2012
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1482-6

Other articles of this Issue 11/2012

Annals of Hematology 11/2012 Go to the issue

Letter to the Editor

Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes

Original Article

Activating CBL mutations are associated with a distinct MDS/MPN phenotype

Original Article

Phytohemagglutinin-activated human T cells induce lethal graft-versus-host disease in cyclophosphamide and anti-CD122 conditioned NOD/SCID mice

Letter to the Editor

Deep vein thrombosis associated with factor V inhibitor followed by immune thrombocytopenia

Original Article

Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan

Original Article

Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits